Insulin Delivery Devices Market Estimated to Flourish CAGR of 8.7% by 2025 | Top Leading Key Players are Sanofi, Biocon, Owen Mumford, Insulet Corporation, Tandem Diabetes Care, Eli Lilly and Company

The Global Insulin Delivery Devices Market report focuses on an in-depth segmentation of Global insulin delivery devices market, based on product segmented into insulin pens, insulin pumps, insulin syringes, pen needles and others. The geographic segmentation of the report covers five major regions including; North Americas, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SA). The regional market has been further bifurcated by respective countries. By function segment, large enterprises is accounted for largest share in the Insulin Delivery Devices market in 2018, However, insulin pens segment held the largest share of the market by product type. The insulin pumps segment is expected to grow at the fastest rate during the coming years.

‘Insulin Delivery Devices Market to 2025 By Product (Insulin Pens, Insulin Pumps, Insulin Syringes, Pen Needles, and Others), End User (Patients/Homecare and Hospitals & Clinics), and Geography - Global Analysis and Forecasts by Product and End User, the global insulin delivery devices market was valued at US$ 11,869.0 Mn in 2017 and is estimated to reach US$ 22,830.0 Mn by 2025. The market is estimated to grow with a CAGR of 8.7% from 2018-2025.

Get Sample PDF Copy @http://bit.ly/2V3lDAQ

Diabetes among geriatric population is a growing public health burden worldwide. It is a major cause morbidity and mortality in ageing population that later largely attributable to various chronic complications. Ageing population is poised to become one of the most significant transformation with a heavy impact on the social and economic level across the globe. These population is growing exponentially worldwide. According to a report of United Nation (2017), there were approximately 962 million people aged 60 or over across the globe in 2017 and was projected to reach to 425 million by 2050.

Key Benefits-
- To provide detailed information regarding the major factors (drivers, restraints, opportunities, challenges, and trends) influencing the growth of the global Insulin Delivery Devices Market.
- To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (Latin America and the Middle East & Africa)

The increasing rate of obesity, sedentary lifestyle and improper diet play a major role in increasing diabetes among the population worldwide. Physical activity is important to maintain the blood glucose level. Lack of exercise and unhealthy diet such as diet high in fat and calories increase the risk for the development of obesity and diabetes. Obesity is one of the major issue that affect people of all ages and incomes globally. According to World Health Organization (WHO), in 2016, more than 1.9 billion adults aged 18 years and older were overweight. And out of these over 650 million adults were obese. Hence, this is expected to increase the demand of insulin delivery devices in the coming years.

The major players operating in the insulin delivery devices market
- BD
- Novo Nordisk A/S
- B. Braun Melsungen AG
- Insulet Corporation
- Medtronic
- Tandem Diabetes Care, Inc.
- Eli Lilly and Company
- Biocon
- Owen Mumford, Ltd.
- Sanofi

North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period. North American market is driven by the factors such as, rising geriatric population and increasing prevalence of diabetes in the region.

The increasing advancements in blood glucose (BG) monitoring technology have resulted in improved accuracy, smaller required blood volumes, and the ability to transfer data between the BG meter and insulin delivery devices. For instance, in September 2016, the FDA announced their first automatically automatic glucose monitoring device, Medtronic’s MiniMed 670G which is a hybrid closed looped system that provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes. In addition, in July 2018, Abbott announced to have a FDA approval for the FreeStyle Libre 14 day Flash Glucose Monitoring system that allows people with diabetes to wear the sensor up to 14 days with high accuracy. These advancements are expected to offer increasing demand for the products, hence providing better share to the market players.

Major Table of Content:-

1. INTRODUCTION 25
1.1 SCOPE OF THE STUDY 25
1.2 THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE 25

2. GLOBAL INSULIN DELIVERY DEVICES MARKET – KEY TAKEAWAYS 26

3. GLOBAL INSULIN DELIVERY DEVICES MARKET – MARKET LANDSCAPE 28
3.1 OVERVIEW 28
3.2 MARKET SEGMENTATION 28
3.2.1 Insulin Delivery Devices Market – By Product 29
3.2.2 Insulin Delivery Devices Market – By End User 30
3.2.3 Insulin Delivery Devices Market – By Geography 30
3.3 PEST ANALYSIS 31
3.3.1 North America – PEST Analysis 31
3.3.2 Europe – PEST Analysis 34
3.3.3 Asia Pacific – PEST Analysis 36
3.3.4 Middle East & Africa – PEST Analysis 39
3.3.5 South & Central America – PEST Analysis 41

Ask for Discount @ http://bit.ly/2V3lDAQ

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact us
The Insight partners,
Phone: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.